Stephani Klingeman Plati

Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2–associated schwannomas reveals differences in efficacy and drug resistance development

Marisa A. Fuse, Christine T. Dinh, Jérémie Vitte et al. · Neuro-Oncology · 2019 · 39 citations · Full text

Medicine, Cancer Biology, Oncology +17

Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells

Alejandra M. Petrilli, Jeanine Garcia, Marga Bott et al. · Oncotarget · 2017 · 35 citations · Full text

Life Sciences, Cell Biology, Oncology +17

Combination Therapy with c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma Cells

Marisa A. Fuse, Stephani Klingeman Plati, Sarah S. Burns et al. · Molecular Cancer Therapeutics · 2017 · 35 citations · Full text

Medicine, Oncology, Pharmacology +17

Chromosomal abnormalities and copy number variations in fetal left‐sided congenital heart defects

F. A. R. Jansen, Mariëtte J.V. Hoffer, C. L. van Velzen et al. · Prenatal Diagnosis · 2015 · 16 citations · Full text

Medicine, Genetics, Molecular Genetics +17

Peroxynitrite supports a metabolic reprogramming in merlin-deficient Schwann cells and promotes cell survival

Jeanine C. Pestoni, Stephani Klingeman Plati, Oliver D. Valdivia Camacho et al. · Journal of Biological Chemistry · 2019 · 14 citations · Full text

Life Sciences, Cell Biology, Oncology +17